Organovo acquires Metacrine's FXR program for $4M cash

VivoSim Labs, INC.

Total cash consideration of $4M; $2M paid at closing and $2M due after transfer of program.
Acquired FXR program from Metacrine, targeting NASH and liver diseases.
Purchase Agreement entered into and closed on March 10, 2023.
Customary representations, warranties, and closing conditions included.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

VivoSim Labs, INC. entered into Purchase Agreement with Metacrine, Inc. valued at $4 million (effective 2023-03-10).

Action: entry
Agreement: asset purchase
Counterparty: Metacrine, Inc.
Value: $4 million
Effective: 2023-03-10

Exact text from the filing

On March 10, 2023, Organovo, Inc. (“Organovo”), a wholly-owned subsidiary of Organovo Holdings, Inc., entered into and closed an asset purchase agreement (the “Purchase Agreement”) with Metacrine, Inc. (“Metacrine”).

View on SEC.gov

Browse all material agreements →

VivoSim Labs, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-071465

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.